Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: Current perspective and ongoing trials
Göster/ Aç
Erişim
info:eu-repo/semantics/embargoedAccessTarih
2021Yazar
Wang, Alex Z.Lebastchi, Amir H.
O'Connor, Luke P.
Ahdoot, Michael
Mehralivand, Sherif
Yerram, Nitin
Taneja, Samir S.
George, Arvin K.
Sanchez-Salas, Rafael
Ward, John F.
del Pilar Laguna Pes, Maria
de la Rosette, Jean J. M. C. H.
Pinto, Peter A.
Üst veri
Tüm öğe kaydını gösterKünye
Wang, A. Z., Lebastchi, A. H., O'Connor, L. P., Ahdoot, M., Mehralivand, S., Yerram, N. ... Pinto, P. A. (2021). Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: Current perspective and ongoing trials. World Journal of Urology, 39(3), 729-739. https://dx.doi.org/10.1007/s00345-020-03525-0Özet
Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical "middle ground" in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy.